Topotecan – Advanced ovarian cancer

Drug Name (Brand)	Topotecan *(Hycamtin®)*
Indication	Advanced ovarian cancer
Traffic Light Classification	Red
NICE TA (plus link)	Overview \| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer \| Guidance \| NICE
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. May 2005: NICE reviewed Technology Appraisal guidance No’s 28, 45 and 55, topotecan, pegylated liposomal doxorubicin HCl and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer issuing TA 91 * Topotecan is now only recommended for the treatment of women with platinum-refractory or platinum-resistant ovarian cancer if PLDH and paclitaxel are considered unsuitable. * Paclitaxel in combination with platinum-based therapy is now recommended as a treatment option for women whose disease relapses after 6 months of first-line platinum-based therapy. * Within these recommendations, women who have received paclitaxel as part of their first-line treatment may receive paclitaxel as part of their second-line (or subsequent) treatment. * PLDH is now recommended as a treatment option for women whose disease does not respond to, and those women whose disease relapses within 12 months from, initial platinum-based therapy. April 2013: NHS England SCG took over commissioning responsibility for this treatment.
Date of TAG recommendation / ratification		7/1/2005	Review Date	7/1/2007